A randomized, double-blinded clinical pilot study to assess whether addition of inhaled levofloxacin 240 mg twice daily for three days leads to improved or worsened physiological status in CAP patients with and without pre-existing lung disease.
Hospital admission within 24 hours.
Radiologically new-onset chest infiltrate that is consistent with pneumonia and symptoms or signs also consistent with pneumonia, such as fever, cough, sputum, dyspnoea and/or chest pain
CURB-65 score 3-5
C-reactive protein >50 OR central body temperature >38.0 °C (1-2 of these fulfilled)
Septic shock according to the sepsis III criteria:41 sequential organ failure assessment (SOFA) score ≥2) and suspected infection (according to attending physician) and persisting hypotension requiring vasopressors to maintain MAP≥65 mmHg and serum lactate level>2 mmol/L (18 mg/dL) despite adequate volume resuscitation (30 mL/kg crystalloid within 3 hours).
Oxygen requirement ≥5 L/min to maintain acceptable saturation assessed by the treating physician.
Respiratory rate >24/min with relevant oxygen therapy
Positive COVID or influenza test (PCR or antigen test)
6
Treatment groupsSee each treatment group below.